Size | Price | |
---|---|---|
10mg | ||
25mg | ||
50mg | ||
100mg | ||
250mg |
Purity: ≥98%
TAK-778, a derivative of ipriflavone, has been shown to induce bone growth both in vitro and in vivo. Recently, it has been shown that TAK-778 can enhance osteoblast differentiation of human bone marrow cells via an estrogen receptor (ER)-dependent pathway. TAK-778 enhanced bone formation in OVX rats and that this effect was dependent on an ER-mediated pathway.
ln Vitro |
It has been demonstrated that the isoflavone derivative TAK-778 stimulates bone formation in both in vitro and in vivo models. Increased mineralized nodule area was seen after 1 to 21 days of continuous treatment with TAK-778 (10 μM). Cellular alkaline phosphatase (ALP) activity is considerably stimulated by TAK-778 at doses of 1 μM or above. Confluent-stage cells' DNA content rose by TAK-778, albeit not very much. Additionally, from days 5 to 7, TAK-778 administration led to a dose-dependent increase in the amount of soluble collagen and osteocalcin secreted into the culture medium. TAK-778 increased the secretion of TGF-β and IGF-I at every stage of the treatment. 21 days devoted to culture. TAK-778 treatment of the cells increased the saturated cell density in a dose-dependent manner but did not cause ALP activity. Saturated cell density is dramatically reduced by TAK-778 at a dose of 10 μM [2].
|
---|---|
ln Vivo |
Following a single topical application of TAK-778/PLGA-MC (0.2 to 5 mg/site), the radiopaque area generated in the defect increased in a dose-dependent manner. According to histological investigations, a bony bridge filled the deficiency area, and the newly produced radiopaque area, which was encircled by cuboidal osteoblasts and thick osteoid seams, matched to calcified bone encompassing the medullary cavity. No discernible variations were observed in the indices between the skulls treated with TAK-778/PLGA-MC and placebo. TAK-778/PLGA-MC particles triggered radioactive bone repair across the defect two months post-surgery [2]. When OVX mice were given TAK-778 orally, their lumbar spine bone mineral density (BMD) increased more than that of vehicle controls [3].
|
References |
[1]. Rosa AL, et al. TAK-778 enhances osteoblast differentiation of human bone marrow cells via an estrogen-receptor-dependent pathway. J Cell Biochem. 2004 Mar 1;91(4):749-55.
[2]. Notoya K, et al. Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J Pharmacol Exp Ther. 1999 Sep;290(3):1054-64. [3]. Cai M, et al. TAK-778 induces osteogenesis in ovariectomized rats via an estrogen receptor-dependent pathway. J Bone Miner Metab. 2011 Mar;29(2):168-73 |
Molecular Formula |
C24H28NO7PS
|
---|---|
Molecular Weight |
505.5204
|
CAS # |
180185-61-9
|
SMILES |
O=C(NC1=CC=C(CP(OCC)(OCC)=O)C=C1)[C@@H](C2)S[C@@H](C)C(C3=C2C=C4OCOC4=C3)=O
|
Synonyms |
TAK-778 ; TAK 778 ; TAK778
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9782 mL | 9.8908 mL | 19.7816 mL | |
5 mM | 0.3956 mL | 1.9782 mL | 3.9563 mL | |
10 mM | 0.1978 mL | 0.9891 mL | 1.9782 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.